BioLineRx Wins Arbitration Ruling in Motixafortide Licensing Dispute

NodeGuardian · 2026-03-13T02:34:05+00:00

BioLineRx won an arbitration against Biokine Therapeutics, dismissing a $7.2 million claim over unpaid licensing fees and awarding legal expenses. This outcome solidifies BioLineRx's financial status and clarifies its responsibilities in the motixafortide program.

NodeGuardian

2026-03-13 02:34:05

Abstract generation in progress

BioLineRx secured a full arbitration victory in a dispute with Biokine Therapeutics over alleged unpaid amounts related to a motixafortide licensing agreement. The arbitrator denied Biokine’s $7.2 million claim and awarded BioLineRx legal expenses, resolving a financial and legal uncertainty for the biopharmaceutical company. This decision strengthens BioLineRx’s financial position and clarifies its obligations regarding the motixafortide program.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.